Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6857554 | 0.93 | ADRB3 (0.53) | ADRB3ADRA2BADRA2CCTSSCYP3A4 | |
| SCHEMBL6857544 | 0.92 | ADRB3 (0.55) | ADRB3ADRA2BADRA2CCTSSCYP3A4 | |
| SCHEMBL6857555 | 0.91 | ADRB3 (0.54) | ADRB3ADRA2BADRA2CCTSSCYP3A4 | |
| SCHEMBL6857377 | 0.91 | ADRB3 (0.49) | ADRB3ADRA2BADRA2CCTSSCYP3A4 | |
| SCHEMBL6857125 | 0.86 | ADRB3 (0.46) | ADRB3ADRA2BADRA2CCTSSCYP3A4 | |
| SCHEMBL6857557 | 0.85 | CTSS (0.58) | ADRB3ADRA2BADRA2CCTSSCYP3A4 | |
| SCHEMBL6857375 | 0.84 | ADRB3 (0.50) | ADRB3ADRA2BADRA2CCTSSCYP3A4 | |
| SCHEMBL6856842 | 0.84 | CYP3A4 (0.47) | ADRB3ADRA2BADRA2CCTSSCYP3A4 | |
| SCHEMBL6857431 | 0.84 | ADRB3 (0.50) | ADRB3ADRA2BADRA2CCTSSCYP3A4 | |
| SCHEMBL6857541 | 0.83 | ADRB3 (0.49) | ADRB3ADRA2BADRA2CCTSSCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389560-B2 | HCV protease inhibitors | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2013-03-05 | — | — | US | disclosed |
| US-8389560-B2 | HCV protease inhibitors | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2013-03-05 | — | — | US | disclosed |
| US-20110065737-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2011-03-17 | — | — | US | disclosed |
| US-20110065737-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065737-A1 | HCV PROTEASE INHIBITORS | RNASE1, HAVCR2, CTRL | ADRB3 4354/4885ADRA2B 4578/4885ADRA2C 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.